Posted by Michael Wonder on 28 Nov 2023
FDA fast track designation granted for Vaxinia trial program
28 November 2023 - FDA fast track designation for bile duct cancer granted for CF33-hNIS (Vaxinia) MAST clinical program.
Imugene is pleased to announce its MAST (Metastatic Advanced Solid Tumours) clinical program evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (Vaxinia), has been granted fast track designation from the US FDA.
